Ramona Vesna Untanu1, Jason Back1,2, Burton Appel3, Qinglin Pei4, Lu Chen5, Allen Buxton6, David C Hodgson7, Peter F Ehrlich8, Louis S Constine9, Cindy L Schwartz10, Robert E Hutchison1. 1. Division of Clinical Pathology, Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York. 2. Department of Pathology, Chatham-Kent Health Alliance, Chatham, Ontario, Canada. 3. Hematology/Oncology, Institute for Pediatric Cancer & Blood Disorders, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey. 4. Children's Oncology Group, Department of Biostatistics, University of Florida, Gainesville, Florida. 5. Department of Information Sciences, City of Hope, Duarte, California. 6. Statistics, Children's Oncology Group, Monrovia, California. 7. Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 8. Department of Surgery, University of Michigan, Ann Arbor, Michigan. 9. Department of Radiation Oncology, University of Rochester, Rochester, New York. 10. Children's Hospital of Wisconsin, Department of Oncology, Milwaukee, WI, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample. RESULTS: Fifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern, and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect. CONCLUSIONS: Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.
BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample. RESULTS: Fifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern, and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect. CONCLUSIONS: Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.
Authors: G Karayalcin; F G Behm; P W Gieser; F Kung; M Weiner; C K Tebbi; C Ferree; R Marcus; L Constine; N P Mendenhall; A Chauvenet; S B Murphy Journal: Med Pediatr Oncol Date: 1997-12
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Katharine H Xing; Joseph M Connors; Anky Lai; Mubarak Al-Mansour; Laurie H Sehn; Diego Villa; Richard Klasa; Tamara Shenkier; Randy D Gascoyne; Brian Skinnider; Kerry J Savage Journal: Blood Date: 2014-04-08 Impact factor: 22.113
Authors: Richard B Wilder; Pamela J Schlembach; Dan Jones; Gregory M Chronowski; Chul S Ha; Anas Younes; Fredrick B Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D Cox Journal: Cancer Date: 2002-03-15 Impact factor: 6.860
Authors: Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544